Evaluate Your Anti-Obesity Agents with CrownBio End-to-End Preclinical Solutions
Obesity has become a serious epidemic issue with >600 million obese people worldwide.
The molecular and cellular mechanisms of obesity-associated health problems are not yet fully elucidated, therefore requiring preclinical technologies and models to further obesity research and evaluate anti-obesity agents.
Discover CrownBio's Comprehensive Set of Models
CrownBio’s preclinical CardioVascular and Metabolic Disease (CVMD) Translational Technology Platforms provide spontaneous & diet-induced obesity (DIO) models, to support the transition of new agents into the clinic. These include highly translatable models such as:
 |
 |
As well as all available conventional rodent models, with natural or induced obesity, including:
- Zucker fa/fa and Sprague-Dawley (SD) rat
- ob/ob mouse
- DIO in rats and mice
Choose From a Wide Variety of Study Endpoints
Our obesity study endpoints cover a full range of assays and read outs, including assessment of:
- Food intake/body weight (BW) changes,
- Body fat composition (DEXA, qNMR),
- Food consumption (BioDAQ),
- Oxygen consumption/energy expenditure (OxyMax)
- Serum glucose and lipids measurement
- Biomarker ID (hormones and lipids)
Contact us today to discuss your obesity project needs and experience the value of our expert translational service.
